Investegate |Junshi Biosciences Announcements | Junshi Biosciences: Junshi Biosciences and Coherus Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

Investegate announcements from Junshi Biosciences, Junshi Biosciences and Coherus Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

Related Keywords

Guangzhou ,Guangdong ,China ,Shanghai ,United States ,Suzhou ,Jiangsu ,Beijing ,Maryland ,Canada ,San Francisco ,California ,Chinese ,American ,Patricia Keegan ,Denny Lanfear ,Mcdavid Stilwell ,Junshi Biosciences ,Theresa Lavallee ,Coherus Biosciences ,Zhi Li ,Kelli Perkins ,American Society Of Clinical Oncology ,Institute Of Microbiology ,Ir Team ,Coherus Biosciences Inc ,Chinese Academy ,Drug Administration ,Shanghai Junshi Biosciences Co Ltd ,Exchange Commission ,National Medical Products Administration ,Pr Team ,Coherus Announce ,United States Food ,Biologics License Application ,Prescription Drug User Fee Act ,Chief Medical Officer ,Chief Development Officer ,American Society ,Clinical Oncology ,Breakthrough Therapy ,Orphan Drug ,Emergency Use Authorizations ,Private Securities Litigation Reform Act ,Coheru Quarterly Report ,Biosciences Contact Information ,Contact Information ,Investegate Announcements ,Investegate Company Announcements ,Lobenewswire ,Lobenewswire And Globenewswire ,Nw ,